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Major histocompatibility  complex (MHC) class  11-asso- 
ciated  invariant  chain  (Ii)  gene  and  the MHC class I1 
molecules are physically and functionally associated 
within class 11-expressing cell types. These genes are 
generally  co-expressed  in  various  cell  types  and  coordi- 
nately  induced  by  cytokines  such  as  interferon-y (IFN- 
y). Human  Ii  gene  shares a regulatory  mechanism  with 
MHC class I1 genes  via  the X and Y cis-acting  elements. Ii
X and Y are  required  for  constitutive  expression  in B 
lymphoid  cell  lines  and  for  induction by  IFN-y in  a  glio- 
blastoma cell line. The Servenius element ( S )  contrib- 
utes  6-fold  transcriptional  activity  to  class n gene HLA- 
DRA, and  an S homologue  has  been  implied  in  Ii  gene 
regulation. Now  we  report  that  along  with X and Y, the  Ii 
S box functions in a  positive  manner  to  regulate  Ii  tran- 
scription  in B cell  lines  but  not  in T cell  lines. In addi- 
tion, S, X, and Y are  all  necessary for induced  expression 
of  Ii in  an  IFN-yregulated  glioblastoma  cell  line  and  in 
primary  untransformed  glial cells. Transcriptional  ac- 
tivity of  Ii X and Y elements  correlates  with  the  presence 
of in vivo proteidDNA  interactions  in  Ii-expressing  cells. 
Most  interestingly,  in  vivo interactions are induced  upon 
IFN-y  induction  in a  time-dependent  fashion.  Thus,  the 
Ii  promoter contains  elements  that  coordinately  regu- 
late  expression  with  the MHC class I1 genes, and these 
functional sites are  contacted  in  vivo  emphasizing  their 
importance  in  Ii  gene  transcription. 
Major histocompatibility complex (MHC)’ class 11-associated 
invariant  chain (Ii) is functionally and physically linked  to  the 
MHC class I1 heterodimer  in cells. They co-associate in  intra- 
cellular compartments; however, they  are dissociated on the 
cell surface. Results from biochemical and functional studies 
have shown that Ii is needed for the  targeting of properly folded 
class I1 antigens  to  appropriate  intracellular o ganelles and for 
the regulation of class I1 binding of exogenous foreign antigenic 
peptides (1, 2). That  Ii plays a definite role in MHC class I1 
function in development and elicitation of the  immune system 
is demonstrated  in  the  recent  data from Ii-negative mice (3). 
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These mice have  antigen  presenting cells (APC) with reduced 
capacity to function in antigen presentation, and they have 
reduced numbers of CD4+ cells in  the thymus. 
Although encoded on separate chromosomes, Ii and MHC 
class I1 proteins are coordinately expressed in  the  same cell 
types: B lymphocytes, antigen-presenting cells, and  activated 
human T cells (4-6). They are simultaneously induced by  cy- 
tokines such as interleukin-4 (7, 81, tumor necrosis factor-a 
(TNF-a) (91, and y-interferon (IFN-y). IFN--y stimulates expres- 
sion in various cell types including fibroblasts, endothelial 
cells, mast cells, macrophages, and  brain glial cells (10-13). 
Coordinate regulation of class I1 and Ii is at the level of tran- 
scription. However, co-expression is not absolute for a number 
of cases. Some cell lines  have been  established that lack  class I1 
but produce Ii mRNA, including lymphoid cell lines from class 
11-negative bare lymphocyte syndrome patients (14). Differen- 
tial expression has been observed in  certain  tissues of IFN-y- 
treated mice (5). In  human  studies, coordinate  expression has 
been reported in  human  tissues (15, 16)  and  in cells in  tissue 
culture (17); however, noncoordinate expression has also been 
described in colorectal mucosa and B cell lymphomas (4, 18). 
cis-Acting DNA elements  mediate coordinate  regulation be- 
tween Ii  and  the class I1 genes. The promoters of all human  and 
murine  class I1 genes  contain the  class I1  box which consists of 
two conserved sequences, the 15-bp  element (X) and  the 10-bp 
element (Y) with an  intervening 18-21-bp spacer of variable 
sequence and conserved length (19). In  the  human  Ii gene and 
the class I1 gene HLA-DRA, the class I1 box is responsible for 
high constitutive expression in B lymphocytes (20-22) and 
IFN-y responsivity in glioblastoma cell lines (21, 23). These 
same sequences in the murine Ii promoter are involved in 
IFN-y induction in  human fibroblasts (24) and  have been iden- 
tified as  an  enhancer for the proximal promoter located -120 to 
+1 in  the  murine gene (25). The  TNF-a response is controlled by 
the Ii NFKB-like binding site, Ii  KB-1 (26). 
The cis-acting and  trans-acting regulatory elements of the 
MHC class I1 genes have been  characterized (reviewed in Ref. 
22). The promoter of the  human  gene HLA-DRA is  the most 
thoroughly  examined.  The  X  element of  HLA-DRA is comprised 
of two protein  binding sites, X1 and X2. Just  upstream of this 
site is an  element S (also  referred to as W, H, or J) that  acts as 
an  enhancer  (27,28). Several DNA-binding factors that contact 
the class I1 promoter elements  have been detected, and some of 
their genes cloned. HLA-DRA X box-binding factors include 
RFX and hxBP (29,30) which identify the X1 and X 2  elements, 
respectively, and NF-X and  BCF-1(31,32). YEBP is an affinity- 
enriched Y-binding complex which likely contains or corre- 
sponds to  the NFY-A and NFY-B heterodimer known as NF-Y/ 
CBF/CP-1 (31, 33, 34). NF-Y and YEBP are a class of  CCAAT 
box-binding protein and  have been shown in a direct manner  to 
regulate  transcription  using  in vitro transcription  systems (34, 
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35). Significantly, X and Y are bound by protein in vivo in 
expressing cell lines (36, 37) and binding at  the X box is up- 
regulated in  vivo upon IFN-y induction (37). It is known from 
cross-competition experiments in electrophoretic mobility shift 
assays that Ii Y box binding proteins are  the same or similar to 
Y box binding proteins of class I1 genes HLA-DQB and HLA- 
DRA (20L2 
The function of the conserved Ii S element in  Ii basal and 
IFN-y-induced expression remains unexamined. The mecha- 
nism of IFN-y regulation and coordinate induction by IFN-y 
between Ii and class I1 genes remains to be further explored. 
This study extends the analysis of functional Ii promoter ele- 
ments  in expressing, nonexpressing, and IFN-y-inducible cell 
types. This study shows that all three conserved elements, S, X, 
and Y, are important for constitutive expression in these cell 
lines, as well as for IFN-y induction in brain glial cells. We 
compare the function of these elements with their binding char- 
acteristics in vivo and in  vitro. Ii regulatory elements are bound 
in  vivo, and binding correlates precisely with Ii expression in 
the cell types studied. Zn vivo, IFN-y induced proteinDNA in- 
teractions over the  Ii X, Y, and ISRE, as revealed by  genomic 
footprint analysis. Surprisingly, the kinetics of promoter load- 
ing upon IFN-y induction of Ii are different from that of class I1 
gene, HLA-DM. 
MATERIALS AND METHODS 
Plasmids-The  invariant chain promoter-CAT plasmid kspIn790 has 
been described  previously (21), contains sequences from  position  -790 
to +I of Ii gene inserted upstream of the bacterial chloramphenicol 
acetyltransferase (CAT) gene, and in this study is referred to as 
7901iCAT. Constructs with mutant promoter elements were obtained by 
oligo-directed  site-specific mutagenesis using a uracil-containing tem- 
plate (38). Ii Mut X and Ii Mut Y were  previously  described as pInmutX 
and pInmutY', respectively (21). The plasmid Ii Mut S was changed at 
-261 to -255  bp of Ii gene from 5"GAGCCTT-3' to 5"TCTAGAG-3'.  All 
mutations were  confirmed by  DNA sequence analysis. 
Cell  Lines-Ftaji and Namalwa are Epstein Barr virus-transformed 
human B lymphoblastoid  cell lines. H9 is an Ii/MHC class 11-expressing 
human T cell line, and Jurkat and HSB are Ii/MHC class 11-negative 
human T cell lines. All lymphoid  cell lines were maintained in RPMI- 
1640 supplemented with 10% fetal bovine serum and 2 m~ glutamine. 
U-105 MG, which was previously referred to as U-373 MG in this 
laboratory (21, 23,  37,  39, 40), is a human glioblastoma multiform cell 
line and was maintained in McCoy's  5A media, 10% fetal bovine serum, 
and 2 m~ glutamine. Glial cells  were treated with 500 unitdml recom- 
binant  human IFN-y which was generously provided by Biogen. 
Primary cell cultures of rat type I astrocytes were obtained as 
described (41). Briefly, cells were cultured from 1-2-day-old neonate 
Sprague-Dawley rat cerebral cortexes. Cells were grown 2-4 weeks, 
until confluent, and type I astrocytes were purified by a regime of 
differential shaking and adherence to flasks in preparation for trans- 
fection and CAT assay. By immunostaining, cultures were typically 
>95% positive  for GFAP, an astrocyte-specific marker. Cells  were grown 
in Dulbecco's  modified Eagle's  medium, 10% fetal bovine serum, 2 n m  
glutamine, 100 unitdml penicillin, and 100 mg/ml streptomycin. 
Dansfection and CAT Assay-Transfection of various cell lines was 
performed by electroporation as described (21). Extracts were  made of 
the transfected cells and assayed for CAT activity by using [3H]acetyl 
coenzyme A (42) or using [14Clchloramphenicol (43). 
Nuclear Extract Preparation and Electrophoretic  Mobility Shifi As- 
say (EMSAl-Nuclear extracts were prepared as per Dignam et al. (44). 
EMSA was performed as described (45) with the following modifica- 
tions. The binding reaction was MgCl,-free, the electrophoresis was 
in 0.5 x Tris borate buffer without recirculating the buffer, and the gel 
was fixed in 10% acetic acid and 10% methanol before drying. The 
probes  were annealed and radiolabeled oligonucleotides with the fol- 
lowing  sequences:  Ii X+Y was 5'-AATTCCCCAGAAACAAGTGAT- 
GAGGGCCCTGGGCAGCCAATGGGG-3' and Ii S was  5'"MC4.4- 
AGAGCC'ITATGAATCCAAAGGCCTG-3'. 
In vivo Genomic Footprinting-The dimethyl sulfate (DMS) treat- 
ment of cell cultures, DNA preparation, and ligation-mediated PCR 
A. M. Brown, unpublished observations. 
(LMPCR)  were  performed as described (37, 46).  The invariant chain- 
specific primers were as follows  (from 5' to 3'). For the coding strand 
(upper strand): primer 1, CTC'lTAAAGTCGGTGCTG, primer 2, GC- 
CACTCCGCCCACTTGGTAGATGTG; primer 3, CACTCCGCCCACT- 
TGGTAGATGTGGAAGTG and the noncoding strand (lower strand): 
primer 1, TGAGAAGGGGAGACAAAC; primer 2, CAAAGTGCTM" 
CCTGTCTAGGGAGTGGAC; primer 3, GTGCTLTCCTGTCTAGG- 
GAGTGGACATITGC. 
RESULTS 
Analysis of Zi cis-Acting Promoter Elements in B Cells and 
Zi-positive and Zi-negative T Cells-The Ii promoter contains 
DNA sequences bearing a high degree of  homology to the class 
I1 S, X, and Y elements (Fig. 1). Specifically, an S homologue 
(position -261 to -255 in the  Ii gene) is located at the conserved 
17-bp distance from the Ii X box. In several MHC class I1 genes, 
the S element increases constitutive expression approximately 
3- to 5-fold in B cells and is necessary for inducible expression 
in IFN-y-responsive cells. Based on our previous studies, we 
analyzed the  Ii S element for in  vivo regulatory function. Using 
an oligo-directed mutagenesis procedure on the Ii wild pro- 
moter (79OIiCAT), a complete substitution of the 7-bp Ii S box 
was made (Ii Mut S, see "Materials and Methods"). Transient 
transfection and CAT assays were performed in a variety of cell 
types to analyze Ii S function. When Ii Mut S was transfected 
into the B cell line, Raji, we observed a reduction of CAT ac- 
tivity to 41% of the wild type promoter, 79OIiCAT (Fig. 2). The 
effect of mutating S is not as substantial as mutation of Ii X or 
Y which was previously  shown to be  26% and 27%  of  wild type, 
respectively (21, Fig. 2). 
The constitutive expression of human MHC class I1 and Ii 
genes is limited to B lymphocytes, antigen-presenting macro- 
phages, and dendritic cells. Murine T cells and nonactivated 
human T cells are class 11-negative;  however, human T cells can 
be activated by mitogen or antigen to express class I1 mol- 
ecules. Most human T lymphoblastoid lines are DR-negative 
except  for the H9 (Hut 78) line. To examine Ii regulation in T 
cell lines, 79OIiCAT and Ii Mut S were transfected into H9 cells, 
and no significant difference in  the basal level of  CAT expres- 
sion was observed (Fig. 2). However, mutation of X and Y, when 
compared to the wild type construct, decreased CAT activity to 
18% and 33%, respectively (Fig. 2). Thus, Ii X and Y clearly 
regulate  transcription of Ii  in H9  cells  while S is not involved. 
This is  in contrast to HLA-DRA where S is involved in  tran- 
scription in H9 cells (28). Ii  mutant constructs were also used to 
transfect a class 11-negative T cell line, Jurkat. Unexpectedly, 
the transfected Ii gene construct is expressed in Jurkat  in con- 
trast to the endogenous Ii gene. This suggests that  the genomic 
structure  is not accessible to transcription factors or perhaps 
the excess of transfected Ii promoters titered out a limited 
number of inhibitory factorb). Similar to the  results in H9  cells, 
GENE 8 X Y 
Ii -261 QAQCCTT~---CCCAQAMCMQTGA----AGCCMTGGG -199 
TC-CCC 
I I I I I I I I I I  
DIU -132 GQACCCT"--CCTAQCAACAGATGC----CTQ~GT -66 
q?B -137 GMCCTT""CCCAGAGACAGATQA----CTGmTT -71 
Ea -117 GQACCTQ----CCTAQCMCAQATGT----CT-TT -50  
Aa -107 AQQCCTC-- - -GCTQGCMCGQTQAC-- - -CTQ~TT -40  
Eb -152 Q Q A C C T Q - " - A C T A G C M ~ Q A T Q A - - - - C T G ~ C T  -88 
Ab -123 GAGCCTT----CCCAGAQACAGATGA----CTQwTT -59 
FIG. 1. DNA sequence  homologues of the Ii and MHC class I1 
genes  include  the S, X, and Y elements. Sequences are from  Ref.  19 
except  for Ii which is from Ref.  66. 
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FIG. 2. Constitutive  Ii expression is mediated by promoter el- 
ements in lymphoid cell  lines. The mutations were made in the 
regulatory  elements, S, X, and Y, of Ii  promoter  and their effects were 
assayed by transient transfection  and CAT assay. Raji is the  Ii-express- 
ing B cell line represented by solid bars. H9 is the  Ii-expressing T cell 
line,  represented by hatched bars, and Jurkat is the  Ii-negative T cell 
line,  represented by the open burs.  Relative CAT activity is shown above 
the bars and is CAT activity-normalized to the wild type plasmid 
(79OIiCAT)  which is expressed as 100%. The  mean of at least five indi- 
vidual  experiments is shown and  includes at least two preparations of 
each  plasmid. 
mutation of either X or Y reduced the  basal level of expression 
to 20% and 25%, respectively, while mutation of S had no in- 
fluence on promoter activity. This shows the lack of a function 
for S in  an  additional T cell line. 
Analysis of Ii cis-Acting  Promoter  Elements  in ZFN- y-treated 
Glial Cells-To continue the  characterization of the role of Ii 
promoter homologues in IFN-y-induced Ii  expression, transient 
transfection experiments  in  the glioblastoma cell line, U-105 
MG, were performed. The glioblastoma cell line was utilized as 
a model of inducible expression in brain glial cells. This is 
relevant  to  the induced  expression of  MHC class I1 expression 
observed in  brain glial cells in  certain disease states  such as 
Alzheimer's disease,  multiple sclerosis, and AIDS encephalopa- 
thy (47). Upon IFN-y  treatment,  class I1 protein  expression is 
increased 15-fold in  this glioblastoma cell line. We transfected 
the  Ii wild type  promoter  construct and  the individual mutant 
constructs  and compared the fold induction of  CAT expression 
produced by IFN-y. With the  Ii wild type promoter, IFN--y rou- 
tinely produced a 40-50-fold higher level of CAT expression 
than basal activity in this cell line. Mutation of the S box 
resulted  in a nearly complete loss of IFN-y  induction in  these 
cells compared to wild type -fold induction (Table I).  The  same 
was previously observed in  studies  where X and Y were mu- 
tated  and  are included for comparison here (21, Table I). Thus, 
all three  elements  appear  to cooperate and  are necessary for 
IFN--y induction in  the glioblastoma cell line. 
We also  examined the role of the IFN-y responsive sequences 
in primary, untransformed  cultures of rat type  I  astrocytes. In 
this  analysis, we could test promoter  function in cells which 
more closely represent those in the live animal. These cells 
were obtained from 1-2-day-old neonatal rat cortex and cul- 
tured 2-4 weeks in  tissue  culture flasks. When the wild type 
and  mutant plasmids  were  transfected into  these  cultures,  and 
the resultant cell extracts were analyzed, results similar to 
those  in  the glioblastoma were  obtained. Ii S, X, and Y were all 
required for an  IFN-y response in rat astrocytes (Table I). 
Protein from Nuclear  Extracts Binds Zi X + Y and S in Vitro 
"Nuclear factors have been identified that bind to  the class I1 
S(W), X, and Y elements (22). In  order  to correlate the protein 
binding  activity and  transcriptional function of the  Ii class I1 
homologues and  in  order  to compare in vitro and in vivo binding 
characteristics of these elements, EMSAs were performed with 
Ii S and  Ii X + Y DNA probes. Fig. 3 shows detection of se- 
quence-specific complexes in extracts from Namalwa (lanes 
13), H9 (lanes 4 4 ,  Jurkat (lanes 7-91, and U-105 MG (lanes 
TABLE I 
Effects of promoter mutations on -fold induction by IFN-y 
Cell line Cell type wz Mut S M u t X   M u t Y  
U-105 MG 
Primary  cultures  Rat type I astrocyte 7 2.9 1.8 2.8 
Human  glioblastoma 45 2.2 2.2 8.5 
10-16) using a 45-bp radiolabeled  Ii X + Y probe. Competition 
with homologous cold competitor blocked specific complex for- 
mation (lanes 2, 5, 8, and 11) while an  unrelated competitor 
oligonucleotide did not (lanes 3, 6, 9, 12, and 13). In addition, 
nuclear extracts from U-105 MG were prepared from cells 
treated with IFN-y, and these were analyzed in EMSA. No 
differences in  the  number of complexes formed or the  amount of 
protein bound between treated  and  untreated cells could be 
detected using  this  assay (Fig. 3,  compare lanes 14 and 10). The 
Ii S element also was bound by sequence-specific complexes 
from Namalwa, H9, Jurkat, IFN-y treated, and untreated 
U-105 MG nuclear  extracts (Fig. 4). Again, IFN-y did not alter 
the  pattern of binding. Thus, binding of protein to the X + Y or 
S sequence, in cell-free lysates, occurs regardless of class I1 
promoter activity. 
Zn Vivo Genomic Footprinting of Zi Promoter-Zn vitro bind- 
ing  studies show that  the  Ii promoter elements bind indistin- 
guishable  protein complexes in  nuclear  extracts of B cells, T 
cells, and glioblastoma cells regardless of the  status of endog- 
enous Ji gene expression. In  order  to  determine if these  results 
accurately reflect the promoter structure within the nucleus of 
these cells, we determined  the  proteidDNA contacts on the Ii 
promoter in vivo by genomic footprinting. In  this procedure, 
guanine residues are  methylated in vivo with DMS, and  the 
specific interaction of protein with DNA is revealed as reduc- 
tions or enhancements  in  band  intensity at residues  protected 
from subsequent cleavage by piperidine. Briefly, the procedure 
is  as follows, DNA prepared from various cell lines that  have 
been DMS-treated in  culture was  digested with EcoRI and pi- 
peridine-cleaved in  vitro. The DNA fragments were amplified 
and radiolabeled using ligation-mediated PCR (LMPCR) (46) 
and resolved on a standard sequencing gel (37). The control is 
deproteinated genomic DNA which has been methylated  with 
DMS in  vitro. 
Fig. 5A shows footprinting on Ii DNA in  the Ii-expressing cell 
lines Raji and H9 and  in  the nonexpressing cell line  Jurkat. 
Clear protections  were observed on guanine residues on both 
strands of the X box and  the Y element  in Raji cells and  in  H9 
cells (Fig. 5A,  lanes 1 4 ,  and  summarized  in Fig. 6). However, 
no protections or enhancements were formed on the Ii promoter 
in  Jurkat cells (lanes 5 and 6 )  which do not  express Ii. The Ii S 
element did not have any reproducible contact  points associ- 
ated  with  it.  The  same  results were also  obtained with  the B 
cell line  Namalwa which mimicked the Raji footprint and  the 
nonexpressing  T cell line,  HSB, which was completely unpro- 
tected as  in  the  Jurkat cells (data not shown). Thus, in  vivo 
DNA-protein interaction segregated precisely with gene ex- 
pression.  This is in  contrast  to  data from in vitro binding stud- 
ies shown in Figs. 3 and 4 where nuclear  proteins bind to these 
promoter elements  regardless of gene  expression and  attests  to 
the  value of the in  vivo analysis. 
The  proteinDNA  interactions across the Ii gene promoter 
were also examined in the glioblastoma cell line U-105 MG 
during IFN-y  induction. Prior  to IFN-y  induction, no interac- 
tions were observed on the  5' regulatory region of Ii (Fig. 5B, 
compare lanes 1 and 2 ) .  However, after  IFN-y  treatment,  an 
increase  in protein  binding over a number of Ii promoter ele- 
ments  appeared (lanes 3-51. Protections at Ii X and Y began at 
4  h and were  maximal at 24 h after IFN-y  induction. Identical 
guanine residues  were  contacted  in the induced cells as in  the 
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U-105 MG 
Namalwa H9 Jurkat 
8 4 b 
FIG. 3. EMSA reveals Ii X + Y-spe- comp c . r " + ; ' ~ \ c * ~  e +x 4" 
cific complexes in nuclear extracts . . -. c . rr ."' 
from  Namalwa-, H9-, Jurkat-, and 
blastoma cell line, U-105 MG. The ,'12P- 
IFN-y-treated and untreated glio- x+y- 
labeled probe is  the 45-bp Ii X + Y se- 4 
quence  (se   "Materials  and Methods"). 4 
The  competitors are  as labeled: lanes I ,  4, 
7, 10, and I4 have  none; lanes 2, 5, 8, 11, 
and 15 contain  unlabeled  45-bp X + Y; and 
lanes 3, 6, 9, 12, 13, and 16 have either 
NF-KB or SP-1 (EG3) binding sites as 
nonspecific cold competitor. All competi- 
tors  were  used a t  100-fold molar excess. 
The unlabeled arrows point to nonspecific 
bands or bands of unknown specificity. 
. .  
c-c 
w I '  - 
I 
Namalwa H9 
1 2 3  4 5 6  7 0 9  
Jurkat U-105 MG 
untreated IFN-y 
"1 
w C" -- "*"" 
1 2  3 4 5 6 7 0 9 1 0 1 1 1 2 1 3 1 4  
Ii-expressing cells Raji and  H9  (summarized  in Fig. 6). Foot- 
printing of the Ii  promoter  also  revealed prokidDNA  interac- 
tions on several other  regulatory motifs. The  Ii ISRE has been 
shown previously to be involved in IFN-y  induction in glioblas- 
toma cells in  the presence of an  intron  enhancer,  making  an 
approximately 2-fold contribution to induced  levels of expres- 
sion (48). Upon IFN-y induction, a single protected guanine 
residue  was observed on the  Ii ISRE that became a t  maximal 
intensity at 24  h (data not  shown, summarized  in Fig. 6). The 
presence of a protein  contact in vivo corresponds to the function 
of the Ii ISRE. 
DISCUSSION 
This  study  examines  the roles of Ii conserved and  distinct 
cis-acting elements  in  mediating  the  transcriptional  regulation 
of Ii  in  constitutive  and IFN-y-induced states. The S, X, and Y 
elements of the Ii  promoter are all involved in high constitutive 
expression in B cells, and X and Y are responsible for consti- 
tutive expression in  H9 cells. Ii S, X, and Y are all necessary for 
IFN-y  induction in glioblastoma. The importance of these ele- 
ments  is highlighted by the  in vivo proteidDNAinteractions on 
15  16  17  18
untreated IFN-.; 
10 11 12  34  516 
c X+Y 
FIG. 4. Ii S box-specific complexes 
in nuclear extracts. The "2P-labeled 
30-bp Ii S element  was  used  as a probe. 
The  nuclear  extracts  and  competitors  are 
as labeled. The Mut S competitor is a 
30-bp sequence with the same sequence 
change  as  in  the  plasmid  Ii  Mut S. Com- 
petitors  were  used a t  100-fold molar ex- 
cess. 
these  sites  during  the constitutive and IFN-y-induced states. 
The in vivo occupancy at these  sites was found to correlate 
precisely with  expression of the  Ii gene, whereas  in vitro bind- 
ing did not. This points to  the significance of in vivo binding 
studies. Promoter  loading on the Ii  binding sites  during IFN-y 
induction was  such  that all sites were  unbound before induc- 
tion, and, upon  IFN-y treatment,  certain G residues in X, Y, and 
the ISRE became protected and/or  enhanced. 
In addition to  the Ii X and Y elements previously analyzed, 
now we show that  the  Ii S box is also a positive regulatory 
element for high  constitutive  expression in B cell lines.  This is 
similar to the function of the S element in  HLA-DM which 
contributes a 3-5-fold enhancement of gene expression. The S 
box in  HLA-DM is similar  in sequence and function to the J 
element which controls  regulation of  HLA-DPA and HLA-DQB 
(49). In  the case of HLA-DM, a J box homologue completely 
overlaps the S element; however, Ii does not appear to have  a J 
homologue. 
The IFN-y  induction of human  Ii gene, MHC class I1 genes 
HLA-DM,  and  the  murine  Aa,  EP  ,and Ii  genes is mediated 
through  the  same  tripartite promoter  elements: S, X, and Y (21, 
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FIG. 5. In vivo genomic  footprint shows protein-DNA interac- 
tions on X and Y in  expressing cell types. The 5' regulatory region 
of Ii  was  footprinted  in vivo using DNA from the following cells: A, Raji 
(lanes 1 and Z ) ,  H9 (lanes 3 and 4 ) ,  Jurkat  (lanes 5 and 6) B,  IFN-y- 
treated U-105 MG a t  0,4,24, and 48 h.  The  region  covering  the Ii S, X, 
and  Y boxes is  shown,  and  these  sequences  are  marked  with brackets. 
The lower strand  is  shown for all cell lines.  Lanes  labeled Con are  the 
G ladders produced with DNA methylated in vitro. DMS marks  the 
lanes with DNA that were DMS-treated in vivo. Open circles mark 
positions of protection. 
S X 
t t  t 
t t  t 
Y ISRE 
FIG. 6. Summary of in  vivo footprint  of Ii regulatory region 
involved  in constitutive and IFN-y regulation. ProteinDNA con- 
tacts on the  distal Ii promoter region were  determined.  The  locations of
protection are indicated by arrows,  and  the position of the  enhancement 
is indicated by the  arrowhead.  The  Ii  functional  regulatory  elements  are 
marked by  boxes. 
23, 24, 50, 51). Similar S and X sequence motifs have been 
described as IFN-y-responsive elements  in  the  murine Fc(y) 
receptor  promoter in monocyte-macrophage cells (52)  and  thus 
represents a major pathway for IFN-y  regulation. This mecha- 
nism for IFN-y-inducible gene  expression appears  to be quite 
different from those pathways described for the other IFN- 
responsive  genes. 
Interferon induction in  many genes is  mediated  through  the 
ICs or IFN consensus  sequence, (AGT"CTCdtTCTC)  in MHC 
class  I  genes, Pz-microglobulin, and  others (53-56). IFN-y-re- 
sponsive elements (ISRE, ICs)  also  mediate  IFN-a  and IFN-P 
induction of IFN-inducible genes (57). Positive and negative 
regulatory factors that bind the ISRE consensus sequences 
may be constitutively  expressed or IFN-inducible and include 
among them IRF-1, IRF-2, NF-KB, and ICSBP (58-61). The 
IFN-y  induction of  MHC class I1 genes is not mediated by the 
ISRE, nor are  these genes regulated by IFN-a  and IFN-P. In 
contrast  to  the class I1 promoters, the  human Ii  gene has  an 
ISRE which confers approximately 2-fold induction in  the pres- 
ence of an  intron  enhancer (48). In  vivo proteidDNA  interac- 
tions over the Ii  ISRE  highlight this function  (Fig. 6)  and cor- 
relate with the  interactions previously observed on an MHC 
class I ISRE (62, 63). Indeed, the  Ii ISRE binds an induced 
complex in  the IFN-y-treated monocyte/macrophage cell line, 
U937, in vitro (48). I t  would be interesting  to  determine  what 
transcription factofis) bind this  site  and  whether Ii expression 
is modulated by Type I  interferons. The Ii  promoter also con- 
tains two NF-&-like target  sites  and  Ii KB-1 appears to be 
involved in constitutive but not IFN-y-induced expression? and 
TNF-a-regulated  expression  (26). 
Protein-DNA interactions on the Ii  promoter were investi- 
gated using in  vitro and in vivo techniques. Mobility shift ex- 
periments revealed X + Y-specific and S box-specific  complexes 
in  nuclear  extracts from all cell types  examined. Protein-DNA 
complexes were observed in  the nonexpressing Jurkat cell line 
as well. The  limitations of in  vitro binding assays  have been 
noted previously by us and  others  (36,46,62-64).  The  analysis 
of a number of promoters and interferon-inducible  genes has 
been  advanced greatly by utilizing in vivo genomic footprinting. 
Using  this technique, we show that Ii X and Y are bound in B 
and T lymphocyte cell lines which have high  constitutive ex- 
pression. The Ii X box which is homologous to  the HLA-DRA XI 
is bound in  vivo; however, the DRA Xz box does not exist  in  the 
Ii promoter. As in HLA-DRA, the S box was not associated  with 
any in  vivo contact points (37). A factor interacting a t  this 
functional site may escape detection by this technique or the 
interaction with the DNA may be of a transient  nature. 
The Ii  promoter in negative cell lines  Jurkat  and HSB were 
entirely unprotected in  vivo as noted on the HLA-DRA pro- 
moter  in  these  same cell lines (37). Thus, in vivo binding cor- 
relates with expression of the endogenous Ii gene. This con- 
trasts with data obtained in  the in  vitro assay where  factors  in 
Jurkat cell nuclear  extracts bind  Ii S, X + Y (Figs. 3 and 4), as 
well as  in  the transfection data in which factors are available 
for transcription  in  Jurkat cells using a transfected  promoter 
(Fig. 2). These observations may be explained a number of 
ways. We believe that,  as described in other genes, transcrip- 
tion is not only regulated at the level of factor  availability but 
at   the level of chromatin structure. For  example,  class  II-nega- 
tive cell lines from bare lymphocyte syndrome patients also 
lack  factor  binding on the class I1 promoters (361, and  these 
authors  suggest  that  the  chromatin  structure  is closed until 
initiation factors/events remove the  structural block. 
Changes  in in vivo proteinDNA  interactions  during  IFN-y 
induction occur on the Ii promoter. The Ii promoter has no 
detectable protein contacts before induction and upon IFN-y 
treatment contacts develop over X, Y, and  the ISRE. Concur- 
rently upon induction,  footprints  were  also observed on one Ii 
NF-KB,  the proximal NF-Y, and  the  SP-1 binding sites  in  the Ii 
proximal promoter region from the -130 to +1  position^.^^^ This 
pattern  is  in  contrast  to  the  pattern of protein  loading on the 
HLA-DRA promoter  where the DRA X and Y are  already pro- 
tected at time 0 and IFN-y causes  an up-modulation of X box 
binding only (37). This indicates that Ii may utilize  a  different 
mechanism of promoter loading. Changes in protein  interac- 
tions  during IFN-y treatment may be explained by the induced 
binding of a previously unbound  protein. However, after exten- 
sive  study,  a novel complex was  not  detected by in  vitro binding 
experiments. It  is possible that IFN-y changes the compart- 
mentalization of factors in  the nuclei, yet such compartmental- 
ization is negated upon cell lysis  required for nuclear extract 
preparation. Alternatively, IFN-y  induction may cause a modi- 
fication(s) in existing bound protein(s) which result in an in- 
A. M. Brown, M. W. Linhoff, B. Stein, K. L. Wright, A. s. Baldwin, 
K. L. Wright, T. L. Moore, A. B. Brown, and J. P.-Y. Ting, manuscript 
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crease  in affinity of low affinity  interactions. Further,  the  si- 
multaneous  changes  in Ii X and Y footprints point to protein- 
protein interactions between complexes bound to X and Y. 
Protein-protein interactions on the class I1 X and Y elements 
are hypothesized due  to spacing requirements between HLA- 
DRA X and Y (40, 65). These studies have shown that  the 
conserved spacing  between X and Y is necessary for constitu- 
tive and IFN-y-regulated transcription of  HLA-DRA. A similar 
protein-protein interaction may be required for the activation 
of the  Ii gene. This  is  particularly likely because the Y element 
of both DRA and  Ii promoters interact  with a similar if not 
identical  protein as demonstrated by in vitro competition anal- 
ysis.' 
Genomic footprinting  revealed that  in addition to the class I1 
regulatory elements, Ii promoter contains  several motifs not 
found in  other  human class I1 including the ISRE. These Ii 
regulatory elements lacking in DRA may be needed for en- 
hancement or fine-tuning of Ii expression since Ii associates 
with not just one class I1 heterodimer  but  with all three, HLA- 
DP, HLA-DQ, and HLA-DR. In addition, Ii is present  in excess 
over the class I1 molecules which correlates  with  the function of 
Ii in competing with endogenous peptides for the antigen-bind- 
ing  site while class I1 is transported to endosomes (1). Also, Ii 
may be a chaperone for other  proteins  aside from the MHC 
molecules. 
In conclusion, conserved elements s, X, and Y have some 
common functions in  the  human Ii  gene and  the MHC class I1 
genes.  They mediate  constitutive expression in B lymphocytes 
and IFN-y-induced expression in IFN-y-regulated cells. Ii X 
and Y are functional elements  in H9, an  Ii-expressing  T cell 
line. In contrast to the HLA-DRA S element, Ii S does not 
function in T lymphoid cell lines. Ii promoter in  vivo proteid 
DNA contacts over Ii functional elements X and Y parallel those 
in HLA-DRA in constitutively  expressing cell lines  and corre- 
lates precisely with in  vivo expression. In IFN-y-inducible glio- 
blastoma cells, the  Ii promoter in vivo proteinDNA interac- 
tions  are not  detected until  IFN-y  treatment;  this differs from 
those  interactions on the HLA-DRA promoter and  suggests  an 
alternate kinetics of promoter loading. 
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